339 related articles for article (PubMed ID: 30444747)
81. [Vismodegib in metastasized basal cell carcinoma].
Reinders MG; Dirix L; Mosterd K; van Doorn R
Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
[TBL] [Abstract][Full Text] [Related]
82. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma.
Dreno B; Basset-Seguin N; Caro I; Yue H; Schadendorf D
Oncologist; 2014 Aug; 19(8):790-6. PubMed ID: 25001266
[TBL] [Abstract][Full Text] [Related]
83. Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery.
Schell AE; Russell MA; Park SS
JAMA Facial Plast Surg; 2013; 15(5):337-43. PubMed ID: 23744451
[TBL] [Abstract][Full Text] [Related]
84. Metastatic spinal cord compression from basal cell carcinoma of the skin treated with surgical decompression and vismodegib: case report and review of Hedgehog signalling pathway inhibition in advanced basal cell carcinoma.
McGrane J; Carswell S; Talbot T
Clin Exp Dermatol; 2017 Jan; 42(1):80-83. PubMed ID: 27905158
[TBL] [Abstract][Full Text] [Related]
85. Mohs surgery vs primary excision for eyelid BCCs.
Tildsley J; Diaper C; Herd R
Orbit; 2010 Jun; 29(3):140-5. PubMed ID: 20497079
[TBL] [Abstract][Full Text] [Related]
86. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma.
Torres A; Niemeyer A; Berkes B; Marra D; Schanbacher C; González S; Owens M; Morgan B
Dermatol Surg; 2004 Dec; 30(12 Pt 1):1462-9. PubMed ID: 15606733
[TBL] [Abstract][Full Text] [Related]
87. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
[TBL] [Abstract][Full Text] [Related]
88. Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective real-life data.
Gürbüz M; Doğan İ; Akkuş E; Ermiş H; Utkan G; Vatansever S; Taş F
Dermatol Ther; 2021 Nov; 34(6):e15122. PubMed ID: 34478210
[TBL] [Abstract][Full Text] [Related]
89. Follicular and cystic regression of locally advanced basal cell carcinoma following short-term neoadjuvant vismodegib therapy.
Mohr M; Schumacher N; Zillikens D; Terheyden P
J Dtsch Dermatol Ges; 2017 Oct; 15(10):1031-1033. PubMed ID: 28898543
[No Abstract] [Full Text] [Related]
90. [Mohs' method of micrographic surgery as treatment for recurrent basal cell carcinoma].
van Baardwijk AA; Verhaegh ME; Krekels GA; Vermeulen AH; Neumann HA
Ned Tijdschr Geneeskd; 1997 Mar; 141(11):524-9. PubMed ID: 9190509
[TBL] [Abstract][Full Text] [Related]
91. Complete remission of advanced, locally invasive basal cell carcinoma with vismodegib.
Glen P; Farrugia D; Farrier J
Int J Oral Maxillofac Surg; 2020 Sep; 49(9):1149-1152. PubMed ID: 32204965
[TBL] [Abstract][Full Text] [Related]
92. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib.
Zargari O; Azimi SZ; Geranmayeh S
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28631369
[TBL] [Abstract][Full Text] [Related]
93. Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.
Chanu P; Musib L; Wang X; Cheeti S; Girish S; Bruno R; Lu T; Reddy J; Jin JY; Caro I
J Invest Dermatol; 2021 Apr; 141(4):930-933. PubMed ID: 32976880
[No Abstract] [Full Text] [Related]
94. Identifying patients at risk for recurrent or advanced BCC.
Hamid O; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1246-52; quiz 1253-4. PubMed ID: 24196332
[TBL] [Abstract][Full Text] [Related]
95. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
Abou-Alfa GK; Lewis LD; LoRusso P; Maitland M; Chandra P; Cheeti S; Colburn D; Williams S; Simmons B; Graham RA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):29-36. PubMed ID: 28523596
[TBL] [Abstract][Full Text] [Related]
96. Rapid wound re-epithelialization and basal cell carcinoma clearance after Mohs micrographic surgery with postoperative photodynamic therapy.
Reddy KK; Hanke CW; Tierney EP
J Drugs Dermatol; 2010 Feb; 9(2):143-8. PubMed ID: 20214177
[TBL] [Abstract][Full Text] [Related]
97. The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome.
Ally MS; Tang JY; Joseph T; Thompson B; Lindgren J; Raphael MA; Ulerio G; Chanana AM; Mackay-Wiggan JM; Bickers DR; Epstein EH
JAMA Dermatol; 2014 May; 150(5):542-5. PubMed ID: 24623282
[TBL] [Abstract][Full Text] [Related]
98. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient.
Cusack CA; Nijhawan R; Miller B; Henien M; Malat G; Doyle A; Abdelmalek M
JAMA Dermatol; 2015 Jan; 151(1):70-2. PubMed ID: 25337679
[TBL] [Abstract][Full Text] [Related]
99. Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old Chinese Boy with Xeroderma Pigmentosum.
Fife D; Laitinen MA; Myers DJ; Landsteiner PB
Pediatr Dermatol; 2017 Mar; 34(2):163-165. PubMed ID: 28297142
[TBL] [Abstract][Full Text] [Related]
100. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience.
Woltsche N; Pichler N; Wolf I; Di Meo N; Zalaudek I
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e144-e145. PubMed ID: 30472793
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
